456 related articles for article (PubMed ID: 30245231)
1. Drug resistance in multiple myeloma.
Robak P; Drozdz I; Szemraj J; Robak T
Cancer Treat Rev; 2018 Nov; 70():199-208. PubMed ID: 30245231
[TBL] [Abstract][Full Text] [Related]
2. Contemporary drug therapies for multiple myeloma.
de la Puente P; Azab AK
Drugs Today (Barc); 2013 Sep; 49(9):563-73. PubMed ID: 24086952
[TBL] [Abstract][Full Text] [Related]
3. Relapsed/Refractory multiple myeloma: defining refractory disease and identifying strategies to overcome resistance.
Siegel DS
Semin Hematol; 2012 Jul; 49 Suppl 1():S3-15. PubMed ID: 22727390
[TBL] [Abstract][Full Text] [Related]
4. Role of epigenetics-microRNA axis in drug resistance of multiple myeloma.
Rastgoo N; Abdi J; Hou J; Chang H
J Hematol Oncol; 2017 Jun; 10(1):121. PubMed ID: 28623912
[TBL] [Abstract][Full Text] [Related]
5. [Daratumumab for multiple myeloma].
Croizier C; Bailly S
Bull Cancer; 2018 Nov; 105(11):985-991. PubMed ID: 30430991
[TBL] [Abstract][Full Text] [Related]
6. [Mechanisms of drug resistance and sensitivity concerning novel agents for multiple myeloma].
Tokuhira M
Rinsho Ketsueki; 2016 May; 57(5):563-74. PubMed ID: 27263780
[TBL] [Abstract][Full Text] [Related]
7. The future of therapy for relapsed/refractory multiple myeloma: emerging agents and novel treatment strategies.
Moreau P
Semin Hematol; 2012 Jul; 49 Suppl 1():S33-46. PubMed ID: 22727391
[TBL] [Abstract][Full Text] [Related]
8. Targeting Intrinsic and Extrinsic Vulnerabilities for the Treatment of Multiple Myeloma.
Anreddy N; Hazlehurst LA
J Cell Biochem; 2017 Jan; 118(1):15-25. PubMed ID: 27261328
[TBL] [Abstract][Full Text] [Related]
9. Blockade of deubiquitylating enzyme Rpn11 triggers apoptosis in multiple myeloma cells and overcomes bortezomib resistance.
Song Y; Li S; Ray A; Das DS; Qi J; Samur MK; Tai YT; Munshi N; Carrasco RD; Chauhan D; Anderson KC
Oncogene; 2017 Oct; 36(40):5631-5638. PubMed ID: 28581522
[TBL] [Abstract][Full Text] [Related]
10. Practical Approaches to the Management of Dual Refractory Multiple Myeloma.
Lee HC; Mark TM; Shah JJ
Curr Hematol Malig Rep; 2016 Apr; 11(2):148-55. PubMed ID: 26898556
[TBL] [Abstract][Full Text] [Related]
11. Epigenetic strategies to reverse drug resistance in heterogeneous multiple myeloma.
Issa ME; Takhsha FS; Chirumamilla CS; Perez-Novo C; Vanden Berghe W; Cuendet M
Clin Epigenetics; 2017; 9():17. PubMed ID: 28203307
[TBL] [Abstract][Full Text] [Related]
12. Current and emerging triplet combination therapies for relapsed and refractory multiple myeloma.
Pantani L; Brioli A; Tacchetti P; Zannetti BA; Mancuso K; Rocchi S; Martello M; Rizzello I; Terragna C; Zamagni E; Cavo M
Expert Rev Hematol; 2016 Mar; 9(3):315-23. PubMed ID: 26634945
[TBL] [Abstract][Full Text] [Related]
13. Lenalidomide and its role in the management of multiple myeloma.
Falco P; Cavallo F; Larocca A; Liberati AM; Musto P; Boccadoro M; Palumbo A
Expert Rev Anticancer Ther; 2008 Jun; 8(6):865-74. PubMed ID: 18533796
[TBL] [Abstract][Full Text] [Related]
14. Tailoring treatment for multiple myeloma patients with relapsed and refractory disease.
Richardson PG; Laubach J; Mitsiades C; Schlossman RL; Doss D; Colson K; McKenney ML; Noonan K; Warren DL; Ghobrial IM; Munshi NC; Anderson K
Oncology (Williston Park); 2010 Mar; 24(3 Suppl 2):22-9. PubMed ID: 20518367
[TBL] [Abstract][Full Text] [Related]
15. Proteasome inhibitor bortezomib for the treatment of multiple myeloma.
Cavo M
Leukemia; 2006 Aug; 20(8):1341-52. PubMed ID: 16810203
[TBL] [Abstract][Full Text] [Related]
16. New developments in the management and treatment of newly diagnosed and relapsed/refractory multiple myeloma patients.
van de Donk NW; Lokhorst HM
Expert Opin Pharmacother; 2013 Aug; 14(12):1569-73. PubMed ID: 23721099
[TBL] [Abstract][Full Text] [Related]
17. Proteasome inhibitors in the clinical setting: benefits and strategies to overcome multiple myeloma resistance to proteasome inhibitors.
Cheriyath V; Jacobs BS; Hussein MA
Drugs R D; 2007; 8(1):1-12. PubMed ID: 17249845
[TBL] [Abstract][Full Text] [Related]
18. Genomic screening for genes silenced by DNA methylation revealed an association between RASD1 inactivation and dexamethasone resistance in multiple myeloma.
Nojima M; Maruyama R; Yasui H; Suzuki H; Maruyama Y; Tarasawa I; Sasaki Y; Asaoku H; Sakai H; Hayashi T; Mori M; Imai K; Tokino T; Ishida T; Toyota M; Shinomura Y
Clin Cancer Res; 2009 Jul; 15(13):4356-64. PubMed ID: 19549772
[TBL] [Abstract][Full Text] [Related]
19. Panobinostat for the treatment of relapsed or relapsed/refractory multiple myeloma: pharmacology and clinical outcomes.
Richardson PG; Harvey RD; Laubach JP; Moreau P; Lonial S; San-Miguel JF
Expert Rev Clin Pharmacol; 2016; 9(1):35-48. PubMed ID: 26503877
[TBL] [Abstract][Full Text] [Related]
20. Multiple myeloma: from front-line to relapsed therapies.
Moreau P; Touzeau C
Am Soc Clin Oncol Educ Book; 2015; ():e504-11. PubMed ID: 25993216
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
